Interleukin-2 receptor and ovarian cancer.
Interleukin-2 receptor (IL-2R) can be detected in serum. We estimated the IL-2R in the serum of 78 women, of whom 30 were diagnosed as having malignant ovarian tumours, five had non ovarian tumours, one had a negative second look laparotomy, 11 had benign ovarian tumours, three had uterine fibroids and 28 were age-matched controls. The results indicated that the serum IL-2R of these patients was significantly elevated in ovarian cancer patients compared to both controls (P < 0.0001) and benign ovarian tumours (P < 0.0002). There were no significant differences in IL-2R levels between stage of disease and degree of differentiation within the ovarian tumour group.
Owens
O J
OJ
Department of Obstetrics and Gynaecology, Glasgow Royal Infirmary, UK.
Taggart
C
C
Wilson
R
R
Walker
J J
JJ
McKillop
J H
JH
Kennedy
J H
JH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000097:blood / Q000276:immunology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012016:Reference Values
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2